|
1.
|
Chen WQ, Zeng HM, Zheng RS, Zhang SW and
He J: Cancer incidence and mortality in china, 2007. Chin J Cancer
Res. 24:1–8. 2012. View Article : Google Scholar
|
|
2.
|
Elsobky E, El-Baz M, Gomha M, Abol-Enein H
and Shaaban AA: Prognostic value of angiogenesis in
schistosoma-associated squamous cell carcinoma of the urinary
bladder. Urology. 60:69–73. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Prevarskaya N, Flourakis M, Bidaux G,
Thebault S and Skryma R: Differential role of TRP channels in
prostate cancer. Biochem Soc Trans. 35:133–135. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Caterina MJ, Rosen TA, Tominaga M, Brake
AJ and Julius D: A capsaicin-receptor homologue with a high
threshold for noxious heat. Nature. 398:436–441. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Neeper MP, Liu Y, Hutchinson TL, Wang Y,
Flores CM and Qin N: Activation properties of heterologously
expressed mammalian TRPV2: evidence for species dependence. J Biol
Chem. 282:15894–15902. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Kanzaki M, Zhang YQ, Mashima H, Li L,
Shibata H and Kojima I: Translocation of a calcium-permeable cation
channel induced by insulin-like growth factor-I. Nat Cell Biol.
1:165–170. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Everaerts W, Gevaert T, Nilius B and De
Ridder D: On the origin of bladder sensing: Tr(i)ps in urology.
Neurourol Urodyn. 27:264–273. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Nilius B, Owsianik G, Voets T and Peters
JA: Transient receptor potential cation channels in disease.
Physiol Rev. 87:165–217. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Prevarskaya N, Zhang L and Barritt G: TRP
channels in cancer. Biochim Biophys Acta. 1772:937–946. 2007.
View Article : Google Scholar
|
|
10.
|
Lehen’kyi V and Prevarskaya N: Study of
TRP channels in cancer cells. TRP Channels. Zhu MX: CRC Press; Boca
Raton, FL: Chapter 17. 2011, PubMed/NCBI
|
|
11.
|
Santoni G and Farfariello V: TRP channels
and cancer: new targets for diagnosis and chemotherapy. Endocr
Metab Immune Disord Drug Targets. 11:54–67. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Gkika D and Prevarskaya N: TRP channels in
prostate cancer: the good, the bad and the ugly? Asian J Androl.
13:673–676. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Ziglioli F, Frattini A, Maestroni U,
Dinale F, Ciufifeda M and Cortellini P: Vanilloid-mediated
apoptosis in prostate cancer cells through a TRPV-1 dependent and a
TRPV-1-independent mechanism. Acta Biomed. 80:13–20.
2009.PubMed/NCBI
|
|
14.
|
Caprodossi S, Lucciarini R, Amantini C, et
al: Transient receptor potential vanilloid type 2 (TRPV2)
expression in normal urothelium and in urothelial carcinoma of
human bladder: correlation with the pathologic stage. Eur Urol.
54:612–620. 2008. View Article : Google Scholar
|
|
15.
|
Yamada T, Ueda T, Shibata Y, et al: TRPV2
activation induces apoptotic cell death in human T24 bladder cancer
cells: a potential therapeutic target for bladder cancer. Urology.
76:509.e1–509.e7. 2010. View Article : Google Scholar
|
|
16.
|
Yang ZH, Wang XH, Wang HP and Hu LQ:
Effects of TRPM8 on the proliferation and motility of prostate
cancer PC-3 cells. Asian J Androl. 11:157–165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Caterina MJ, Schumacher MA, Tominaga M,
Rosen TA, Levine JD and Julius D: The capsaicin receptor: a
heat-activated ion channel in the pain pathway. Nature.
389:816–824. 1997. View
Article : Google Scholar
|
|
18.
|
Liedtke W, Choe Y, Martì-Renom MA, et al:
Vanilloid receptor-related osmotically activated channel (VR-OAC),
a candidate vertebrate osmoreceptor. Cell. 103:525–535. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Ridley AJ, Schwartz MA, Burridge K, et al:
Cell migration: integrating signals from front to back. Science.
302:1704–1709. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Monet M, Gkika D, Lehen’kyi V, et al:
Lysophospholipids stimulate prostate cancer cell migration via
TRPV2 channel activation. Biochim Biophys Acta. 1793:528–539. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Chuang CK, Pang ST, Chuang TJ and Liao SK:
Profiling of matrix metalloproteinases and tissue inhibitors of
metalloproteinases proteins in bladder urothelial carcinoma. Oncol
Lett. 1:691–695. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Monet M, Lehen’kyi V, Gackiere F, et al:
Role of cationic channel TRPV2 in promoting prostate cancer
migration and progression to androgen resistance. Cancer Res.
70:1225–1235. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kader AK, Liu J, Shao L, et al: Matrix
metalloproteinase polymorphisms are associated with bladder cancer
invasiveness. Clin Cancer Res. 13:2614–2620. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Nakajima M, Welch DR, Wynn DM, Tsuruo T
and Nicolson GL: Serum and plasma M(r) 92,000 progelatinase levels
correlate with spontaneous metastasis of rat 13762NF mammary
adenocarcinoma. Cancer Res. 53:5802–5807. 1993.PubMed/NCBI
|
|
25.
|
Stearns ME and Wang M: Type IV collagenase
(M(r) 72,000) expression in human prostate: benign and malignant
tissue. Cancer Res. 53:878–883. 1993.PubMed/NCBI
|
|
26.
|
Kanayama H, Yokota K, Kurokawa Y, Murakami
Y, Nishitani M and Kagawa S: Prognostic values of matrix
metalloproteinase-2 and tissue inhibitor of metalloproteinase-2
expression in bladder cancer. Cancer. 82:1359–1366. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Coussens LM, Fingleton B and Matrisian LM:
Matrix metalloproteinase inhibitors and cancer: trials and
tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Giannelli G, Falk-Marzillier J, Schiraldi
O, Stetler-Stevenson WG and Quaranta V: Induction of cell migration
by matrix metal-loprotease-2 cleavage of laminin-5. Science.
277:225–228. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Noë V, Fingleton B, Jacobs K, et al:
Release of an invasion promoter E-cadherin fragment by matrilysin
and stromelysin-1. J Cell Sci. 114:111–118. 2001.PubMed/NCBI
|
|
31.
|
Mañes S, Llorente M, Lacalle RA, et al:
The matrix metalloproteinase-9 regulates the insulin-like growth
factor-triggered autocrine response in DU-145 carcinoma cells. J
Biol Chem. 274:6935–6945. 1999.PubMed/NCBI
|
|
32.
|
Stetler-Stevenson WG: Matrix
metalloproteinases in angiogenesis: a moving target for therapeutic
intervention. J Clin Invest. 103:1237–1241. 1999. View Article : Google Scholar : PubMed/NCBI
|
